These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 12556574)

  • 1. Patterns of change in the treatment of psychiatric symptoms in patients with probable Alzheimer's disease from 1983 to 2000.
    Lopez OL; Becker JT; Sweet RA; Klunk W; Kaufer DI; Saxton J; DeKosky ST
    J Neuropsychiatry Clin Neurosci; 2003; 15(1):67-73. PubMed ID: 12556574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychotropic drugs in patients with Alzheimer's Disease: a longitudinal study by the Registry of Dementias of Girona (ReDeGi) in Catalonia, Spain.
    Calvó-Perxas L; Turró-Garriga O; Aguirregomozcorta M; Bisbe J; Hernández E; López-Pousa S; Manzano A; Palacios M; Pericot-Nierga I; Perkal H; Ramió L; Vilalta-Franch J; Garre-Olmo J;
    J Am Med Dir Assoc; 2014 Jul; 15(7):497-503. PubMed ID: 24637090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High prevalence of psychotropic drug use among persons with and without Alzheimer's disease in Finnish nationwide cohort.
    Taipale H; Koponen M; Tanskanen A; Tolppanen AM; Tiihonen J; Hartikainen S
    Eur Neuropsychopharmacol; 2014 Nov; 24(11):1729-37. PubMed ID: 25453487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psychiatric symptoms associated with Alzheimer's disease.
    Mendez MF; Martin RJ; Smyth KA; Whitehouse PJ
    J Neuropsychiatry Clin Neurosci; 1990; 2(1):28-33. PubMed ID: 2136060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psychotropic drug use in relation to psychiatric symptoms in community-living persons with Alzheimer's disease.
    Semla TP; Cohen D; Freels S; Paveza GJ; Ashford JW; Gorelick P; Luchins D; Eisdorfer C
    Pharmacotherapy; 1995; 15(4):495-501. PubMed ID: 7479203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psychotropic drugs use and psychotropic polypharmacy among persons with Alzheimer's disease.
    Orsel K; Taipale H; Tolppanen AM; Koponen M; Tanskanen A; Tiihonen J; Gardarsdottir H; Hartikainen S
    Eur Neuropsychopharmacol; 2018 Nov; 28(11):1260-1269. PubMed ID: 30153953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Diagnosis and therapy of behavior disorders in dementia].
    Hock C; Wettstein A; Giannakopoulos P; Schüpbach B; Müller-Spahn F
    Praxis (Bern 1994); 2000 Nov; 89(46):1907-13. PubMed ID: 11111409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical efficacy of lamotrigine and changes in the dosages of concomitantly used psychotropic drugs in Alzheimer's disease with behavioural and psychological symptoms of dementia: a preliminary open-label trial.
    Suzuki H; Gen K
    Psychogeriatrics; 2015 Mar; 15(1):32-7. PubMed ID: 25516380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of acetaminophen on behavior, well-being, and psychotropic medication use in nursing home residents with moderate-to-severe dementia.
    Chibnall JT; Tait RC; Harman B; Luebbert RA
    J Am Geriatr Soc; 2005 Nov; 53(11):1921-9. PubMed ID: 16274373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apathy and depression in Alzheimer's disease are associated with functional deficit and psychotropic prescription.
    Benoit M; Andrieu S; Lechowski L; Gillette-Guyonnet S; Robert PH; Vellas B;
    Int J Geriatr Psychiatry; 2008 Apr; 23(4):409-14. PubMed ID: 17918770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benzodiazepine utilization patterns in Alzheimer's disease patients.
    Lagnaoui R; Moore N; Moride Y; Miremont-Salamé G; Bégaud B
    Pharmacoepidemiol Drug Saf; 2003 Sep; 12(6):511-5. PubMed ID: 14513664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of drug treatments for Alzheimer's disease in France: a study on a national level based on the National Alzheimer's Data Bank (Banque Nationale Alzheimer).
    Tifratene K; Duff FL; Pradier C; Quetel J; Lafay P; Schück S; Benzenine E; Quantin C; Robert P
    Pharmacoepidemiol Drug Saf; 2012 Sep; 21(9):1005-12. PubMed ID: 22718684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease.
    Bodick NC; Offen WW; Shannon HE; Satterwhite J; Lucas R; van Lier R; Paul SM
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 4():S16-22. PubMed ID: 9339268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impaired insight in Alzheimer disease: association with cognitive deficits, psychiatric symptoms, and behavioral disturbances.
    Harwood DG; Sultzer DL; Wheatley MV
    Neuropsychiatry Neuropsychol Behav Neurol; 2000 Apr; 13(2):83-8. PubMed ID: 10780626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Agitation and aggression in Alzheimer's disease: an update on pharmacological and psychosocial approaches to care.
    Gallagher D; Herrmann N
    Neurodegener Dis Manag; 2015; 5(1):75-83. PubMed ID: 25711456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The course of psychiatric and behavioral symptoms and the use of psychotropic medication in patients with dementia in Norwegian nursing homes--a 12-month follow-up study.
    Selbaek G; Kirkevold Ø; Engedal K
    Am J Geriatr Psychiatry; 2008 Jul; 16(7):528-36. PubMed ID: 18591573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends in the utilisation of psychotropic medications in Australia from 2000 to 2011.
    Stephenson CP; Karanges E; McGregor IS
    Aust N Z J Psychiatry; 2013 Jan; 47(1):74-87. PubMed ID: 23144164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The clinical picture and stability of non-cognitive symptoms in patients with Alzheimer's disease].
    Haupt M; Jänner M; Stierstorfer A; Kretschmar C
    Fortschr Neurol Psychiatr; 1998 May; 66(5):233-40. PubMed ID: 9653639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Factors that modify the natural course of Alzheimer's disease].
    López OL; Becker JT
    Rev Neurol; 2003 Jul 16-31; 37(2):149-55. PubMed ID: 12938075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cohort profile: the Finnish Medication and Alzheimer's disease (MEDALZ) study.
    Tolppanen AM; Taipale H; Koponen M; Lavikainen P; Tanskanen A; Tiihonen J; Hartikainen S
    BMJ Open; 2016 Jul; 6(7):e012100. PubMed ID: 27412109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.